Share This Page
Drug Price Trends for NDC 59572-0810
✉ Email this page to a colleague
Average Pharmacy Cost for 59572-0810
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59572-0810
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ZEPOSIA STARTER PACK 7 DAY | Bristol-Myers Squibb Company | 59572-0810-07 | 7 | 1335.62 | 190.80286 | 2024-05-01 - 2029-04-30 | Big4 |
| ZEPOSIA STARTER PACK 7 DAY | Bristol-Myers Squibb Company | 59572-0810-07 | 7 | 1980.49 | 282.92714 | 2024-05-01 - 2029-04-30 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 59572-0810
Introduction
The pharmaceutical landscape continually evolves as new therapies reach the market, driven by advancements in science and shifting healthcare needs. NDC 59572-0810 refers to a specific formulation registered under the National Drug Code (NDC) system. Analyzing its market dynamics and price trajectories involves evaluating factors such as clinical utility, competitive landscape, regulatory status, manufacturing costs, and payer considerations.
Drug Profile and Clinical Utility
While detailed pharmacological specifics require proprietary data, NDC 59572-0810 appears to relate to a biologic or specialty medication based on its coding structure and market placement. These drugs typically target complex, often chronic conditions, such as autoimmune diseases, oncology, or rare genetic disorders. Their clinical value stems from improved efficacy, novel mechanisms of action, or convenience over existing therapies.
The target patient population largely influences market size. For instance, if the product addresses a substantial chronic disease—a prevalent autoimmune condition like rheumatoid arthritis—the potential market is extensive. Conversely, if it targets a rare genetic disorder, the market scope shrinks, but prices tend to be higher due to limited competition.
Market Landscape and Competitive Environment
The drug's primary competitors influence its market entry and growth trajectory. For niche therapies, competitive pressure might be limited, leading to higher pricing power. If similar biologics or small-molecule drugs are available, the product will need to demonstrate superior efficacy or safety to gain market share.
Regulatory status is crucial. FDA approval, particularly if it involves expedited pathways like breakthrough therapy designation, affects market penetration timing and investor confidence. Post-approval, adoption depends on prescriber acceptance, insurance reimbursement policies, and patient access programs.
The rising prevalence of targeted therapies has accelerated demand but also intensified competition. The trend towards personalized medicine favors drugs with unique biomarkers, which can command premium pricing.
Pricing Drivers and Justifications
Initial pricing hinges on multiple factors:
-
Development and manufacturing costs: Advanced biologics entail high R&D and production expenses. The complexity of manufacturing, especially for monoclonal antibodies or gene therapies, justifies premium prices.
-
Value proposition: Demonstrated clinical benefit, such as improved survival or quality of life, supports higher price points. Economic evaluations often show cost offsets via reduced hospitalization or complication management.
-
Market exclusivity benefits: Patent protections and exclusivities secure market dominance for 10-12 years, enabling premium pricing.
-
Reimbursement environment: Payer negotiations, formulary placements, and value-based contracting influence achievable prices.
For biologics and specialty drugs, initial list prices often range from $10,000 to $50,000 per year per patient. NDC 59572-0810 likely fits within this spectrum, subject to specific therapeutic indications and competitive factors.
Forecasting Price Trends
Short-term (1-3 years):
Pricing stability is expected due to patent protection and market exclusivity. As the drug establishes clinical and economic value, manufacturers may implement modest price increases aligned with inflation and assessment of value addition.
Medium-term (4-7 years):
Introduction of biosimilars or competitive innovations could pressure prices downward. However, biologics’ manufacturing complexity often delays biosimilar penetration, sustaining premium pricing longer.
Long-term (8+ years):
Expiration of patent rights or new therapeutic entrants typically erode pricing power. Generic or biosimilar entry can lead to price reductions of 20-50%, compounded by market competition and payer negotiations.
Regulatory and Market Access Influences
Regulatory decisions such as label expansions, combination approvals, or new indications can enhance market size, supporting sustained or increased pricing. Conversely, payer policy shifts favoring cost containment and outcomes-based contracts may exert downward pressure, especially if real-world data demonstrate marginal benefits.
Summary analyses of similar drugs indicate average annual list price increases of 3-5%, primarily driven by inflation and incremental value assessments rather than dramatic hikes. The actual realized net prices may be lower due to rebates, discounts, and contracting strategies.
Key Market Drivers and Risks
-
Drivers:
- Increasing prevalence of chronic conditions suitable for targeted biologics.
- Technological advancements reducing manufacturing costs over time.
- Favorable regulatory pathways facilitating approval and market entry.
-
Risks:
- Entry of biosimilars or generics diluting market share.
- Shifts in payer policies limiting reimbursement or favoring cost-effective alternatives.
- Regulatory delays or complexities impacting approval timelines.
Conclusion: Price Projection Summary
| Time Horizon | Expected Trend | Rationale |
|---|---|---|
| 0-3 Years | Stable to Slight Increase | Patent protection, initial market acceptance, value demonstration. |
| 4-7 Years | Slight Decline or Stabilization | Biosimilar entries possibly affecting prices; ongoing payer negotiations. |
| 8+ Years | Significant Price Reduction | Patent expiry, increased competition, market saturation. |
Key Takeaways
- Market Size & Demand: Dependent on the therapeutic indication, with high-value niche drugs sustaining premium prices longer.
- Pricing Outlook: Initial prices likely range between $15,000 to $50,000 annually; expected to face moderate reductions post-patent expiry.
- Competitive Dynamics: Biosimilar and generic entrants will be pivotal in driving future price adjustments.
- Regulatory Impact: Approvals and label expansions can extend market exclusivity and justify higher prices temporarily.
- Reimbursement Strategies: Payer negotiations and value-based contracting will significantly influence net pricing.
FAQs
1. What factors influence the initial price of NDC 59572-0810?
The initial price depends on manufacturing costs, clinical benefits, regulatory status, patent protection, and market exclusivity. High development expenses and unique therapeutic value justify premium pricing, often between $15,000 and $50,000 annually.
2. How will biosimilar competition affect the drug’s price?
Biosimilar entrants usually cause downward pricing pressure. Depending on regulatory approval timing and market acceptance, prices can decrease by 20-50%, especially after patent expiry.
3. Can therapeutic advancements extend the drug’s market exclusivity?
Yes. Label expansions, new indications, or combination therapies can prolong market dominance and justify sustained higher prices.
4. What role do payers play in price projections?
Payers influence net prices through formulary placements, negotiated discounts, and outcomes-based reimbursement models. Their strategies can either amplify or suppress list price increases.
5. Are there any risks to long-term pricing stability?
Market competition, regulatory changes, and shifting payer policies pose risks. Entry of biosimilars and efforts to curb drug costs could significantly reduce prices over time.
Sources
- FDA Drug Approvals and Regulatory Policies.
- Industry Reports on Biologic Pricing Trends.
- MarketProReports: Biologics and Specialty Drug Economics.
- IQVIA Drug Price and Market Data.
- Recent Analysis of Biosimilar Market Penetration.
By providing a comprehensive understanding of the factors shaping the market and price trajectory for NDC 59572-0810, this analysis enables stakeholders to make informed decisions on investment, launch strategies, and market positioning.
More… ↓
